Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1998
Cash & Equivalents	46.7	101.94	180.37	132.83	81.93	140.42	49.83	22.06	69.48	6.35	Upgrade
Short-Term Investments	35.8	177.19	197.68	510.09	282.05	259.72	193.48	120.47	139.52	172.93	Upgrade
Cash & Cash Equivalents	82.5	279.13	378.05	642.92	363.97	400.13	243.31	142.54	209	179.28	Upgrade
Cash Growth	-70.44%	-26.16%	-41.20%	76.64%	-9.04%	64.46%	70.70%	-31.80%	16.58%	92.50%	Upgrade
Receivables	0.92	3.68	6.01	5.22	36.91	4.67	3.34	4.97	2.52	10.37	Upgrade
Other Current Assets	10.9	17.52	14.71	11.52	4.59	5.72	1.75	2.07	1.06	1.23	Upgrade
Total Current Assets	94.33	300.33	398.77	659.67	405.47	410.52	248.4	149.58	212.58	190.88	Upgrade
Property, Plant & Equipment	52.87	125.53	124.7	112.37	107.22	78.72	31.07	6.56	2.92	1.48	Upgrade
Long-Term Investments	0	29.85	88.17	50.53	21.83	3.5	4.51	0	0	47.26	Upgrade
Goodwill and Intangibles	0	88.28	93.46	100.93	92.43	94.29	1.59	1.59	1.59	3.46	Upgrade
Other Long-Term Assets	18.13	18.52	16.82	15.06	10.57	3.36	1.18	0.17	0.15	0.14	Upgrade
Total Long-Term Assets	70.99	262.18	323.15	278.88	232.04	179.87	38.34	8.31	4.65	52.33	Upgrade
Total Assets	165.32	562.51	721.92	938.55	637.52	590.4	286.74	157.89	217.24	243.21	Upgrade
Accounts Payable	15.26	22.42	9.76	12.55	6.67	21.46	11.04	6.26	8.23	8.7	Upgrade
Deferred Revenue	0	161.16	252.49	336.69	120.14	155.84	57.59	8.61	13.82	22.2	Upgrade
Other Current Liabilities	32.47	-71.86	-134.36	-205.7	-56.94	-98.78	-23.77	-1.58	-1.95	-10.02	Upgrade
Total Current Liabilities	47.73	111.71	127.89	143.55	69.87	78.51	44.86	13.29	20.1	20.88	Upgrade
Long-Term Debt	33.52	38.99	44.06	38.4	41.19	27.69	0	0	0	0	Upgrade
Other Long-Term Liabilities	1.19	116.85	174.64	259.24	93.71	116.94	53.98	8.41	4.7	15.7	Upgrade
Total Long-Term Liabilities	34.7	155.84	218.69	297.64	134.91	144.63	53.98	8.41	4.7	15.7	Upgrade
Total Liabilities	82.43	267.55	346.58	441.18	204.78	223.14	98.84	21.7	24.8	36.58	Upgrade
Total Debt	33.52	38.99	44.06	38.4	41.19	27.69	0	0	0	0	Upgrade
Debt Growth	-14.03%	-11.51%	14.74%	-6.79%	48.77%	-	-	-	-	-	Upgrade
Retained Earnings	-1,406.38	-1,148.55	-956.27	-777.98	-656.99	-562.7	-495.48	-440.91	-369.25	-328.55	Upgrade
Comprehensive Income	-4.6	-8.4	-3.99	5.42	-2.45	-1.44	-0.29	0.02	0	-0.03	Upgrade
Shareholders' Equity	82.89	294.96	375.34	498.23	432.55	366.52	187.9	136.2	192.44	206.63	Upgrade
Net Cash / Debt	48.99	240.15	333.99	604.53	322.78	372.44	243.31	142.54	209	179.28	Upgrade
Net Cash / Debt Growth	-79.60%	-28.10%	-44.75%	87.29%	-13.33%	53.08%	70.70%	-31.80%	16.58%	92.50%	Upgrade
Net Cash Per Share	0.28	1.56	2.31	4.50	2.88	3.84	3.12	2.02	3.00	2.67	Upgrade
Working Capital	46.6	188.62	270.88	516.12	335.6	332.01	203.54	136.29	192.49	170	Upgrade
Book Value Per Share	0.47	1.91	2.60	3.71	3.86	3.78	2.41	1.93	2.76	3.08	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).